There are ca. 10 million patients arising annually.1 The financial cost of treatment and Medicare for AD patients is rising rapidly.1 AD is strongly associated with the self-aggregation of amyloid beta (Aβ) peptides,2,3 which are a heterogeneous mixture of peptides having different solubility, stability, and biological and toxic properties.3,4 These peptides are generated from the single-pass transmembrane amyloid precursor protein (APP) by several proteases at different sites. The gene discussed is APP; the disease is Alzheimer disease.